Drug Trial Radar · NCT02249429
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
Last checked: Nov 19, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
May 2015
Primary completion
Sep 11, 2018
Study completion Sep 11, 2018
Sponsor
- Lead sponsor
- PIQUR Therapeutics AGIndustry
- Sponsor type
- Industry
- Collaborators
- University College London Hospitals; Churchill Hospital; Royal Marsden NHS Foundation Trust; University of Haifa; Weill Medical College of Cornell University; Institut Curie; University Clinical Center, Sarajevo; Clinical Center Kragujevac; Clinical Center Nis, Nis; Institute for Oncology and Radiology Serbia, Belgrade; University Clinical Centre of Republic of Srpska
- First posted
- Sep 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib (PQR309) administered orally, as once daily capsules continuously and on intermittent schedule in patients with relapsed or refractory lymphomas.
Conditions
- Lymphoma, Malignant
Interventions
bimiralisibDrug
60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of Change of Tumor Response Criteria in lymphoma patients During Treatment with PQR309 in patients with relapsed or refractory lymphoma according to Cheston Criteria (5)Time frame: 28 day prior to first treatment (baseline), during treatment every 8 weeks during 6 months and every 6 months afterwards up to 1 year)
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
Weill Cornell Medicine
New York, New York
University Clinical Center Republic of Srpska
Banja Luka, Bosnia and Herzegovina
University Clinical Center Sarajevo
Sarajevo, Bosnia and Herzegovina
Insitute Curie
Saint-Cloud, Paris, France
Univeristy Hospital Haifa
Haifa, Israel
Institute for Oncology and radiology of Serbia
Belgrade, Serbia
Clinical Center Kragujevac
Kragujevac, Serbia
Clinical Center Nis
Niš, Serbia
Guy's Hospital
London, United Kingdom
Royal Marsden NHS Foundation Trust
London, United Kingdom
University College Hospital London
London, United Kingdom
Churchill Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.